Lund, Sweden, March 20, 2026. Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa” or the “Company”) today announces that it has entered into a U.S. convertible note purchase agreement with certain funds managed by Athyrium Capital Management (“Athyrium”), comprising USD 30 million aggregate principal amount of unsecured convertible senior notes (the “Financing”). The Financing extends […]